Physician profile

Michael Pham

Endodontics · Fairfield, CA

NPI 1245607837

$521.95

in general payments reported to CMS, 2019-2025

5 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$144.99
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$54.09

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Septodont INC. $233.61 2021-2024 Bioroot Flow- 2 G
Sonendo INC $143.98 2020-2023 Gentlewave G4 Console, Posterior Cleanflow Procedure Instrument With Matrices
Nusmile, Ltd. $77.79 2023 Zarc Files
Coltene Whaledent INC. $52.73 2020-2021
Peter Brasseler Holdings, LLC $13.84 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Pham

$521.95

in general payments reported 2019-2025

Years
2019-2024
Top company
Septodont INC.

https://glasscript.com/doctor/1333964/michael-pham

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.